• PFS [ Time Frame: 12 months ]
  Progression-free survival (PFS) is defined as the time from the date of the first administration of patients medication plan based on MiniPDX drug sensitivity test to the date of the first documentation of disease progression or death due to any cause, whichever comes first, censored at the last date at which the participant was determined to be progression-free.
• OS [ Time Frame: 12 months ]
  Overall survival is defined as time from initiation to death of any cause.
• ADR [ Time Frame: Up to 30 days of last study treatment. ]
  Adverse Drug Reaction：Adverse events determined according to CTCAE (version 4.03) and attribution to study treatment.
• Clinical Consistency [ Time Frame: Up to 2 months of last study treatment. ]
  Overall clinical consistency（accuracy） as assessed by evaluating Response Evaluation Criteria In Solid Tumors (RECIST) criteria in patient tumor and correlating to tumor regression in Mini-PDX model for same drug treatment.

Inclusion Criteria:

1. Patient can provide detailed clinical baseline information including: name, age, gender, pathology, past treatment, etc.;
2. Male, age ≥ 18 years old;
3. ECOG score 0~2 points;
4. Patient must be able to provide tissue samples for the drug sensitive test;
5. No treatment history with PI3K inhibitors, AKT inhibitors or mTOR inhibitors;
6. Estimated lifetime is ≥ 3 months;
7. Histological or cytologically determined prostate adenocarcinoma, excluding neuroendocrine differentiation, signet ring cell carcinoma and small cell carcinoma;
8. Patient is at a castration level and the testosterone level is lower than <50 ng/dL or 1.7 nmol/L;
9. Received abiraterone or enzalutamide and other new second-generation anti-androgenic drugs and have disease progression. Disease progression is defined by PCWG3 :The progression of disease in PCWG3 is defined as satisfying one of the following: according to the increase in PSA levels, there must be three consecutive increases in PSA at least one week apart, and the minimum value is greater than or equal to 5.0 ng/ml; disease progression as assessed by RECIST 1.1, considering PSA levels or not; PCWG3 defines bone disease progression, which is bone scan found 2 or more new lesions;
10. Evidence of distant metastatic disease (such as bone scans and CT/MRI results), imaging data that can be used to assess the condition before and after treatment, or imaging experience provided by three imaging hospitals with experience in three hospitals. Test reports and oncology indicators include PSA values;
11. The patient can tolerate the primary physician to perform the puncture operation, after receiving the informed consent from the patient and the family members;
12. The follow-up period must be at least greater than 2 months;
13. Be able to follow the research and follow-up procedures to provide real and effective information;
14. The patient or his legal guardian understands the test procedure and content and voluntarily signs the printed informed consent form.

Exclusion Criteria:

1. Cognitive ability and psychological abnormalities
2. ECOG score 3-4 points or blood biochemical examination indicates that the patient is not suitable for continuing chemotherapy or chemotherapy has been postponed
3. Can not provide enough tumor puncture tissue, not enough tumor cells for subsequent experiments;
4. Patient who is unwilling to receive follow-up treatment after the Mini PDX model drug sensitivity test;
5. The investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of this study (for administrative reasons or other reasons).